RVMDRevolution Medicines, Inc.Signing up patients
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Adenocarcinoma Metastatic · Pancreatic Adenocarcinoma · Pancreatic Adenosquamous Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Aug 28, 2026
- Main results expected
- Mar 2029
- Fully finished
- Apr 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Up to approximately 4 years
Overall survival (OS)
Measured over: Up to approximately 4 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT07805954 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC